By Josh White
Date: Thursday 23 May 2024
(Sharecast News) - Avacta Group announced the successful completion of the first cohort and the start of dosing for three patients in the second cohort of the second arm in its phase one trial of AVA6000, a peptide drug conjugate form of doxorubicin chemotherapy, on Thursday.
The AIM-traded company also initiated...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news